An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.

Inclusion Criteria: * The subject has provided written informed consent with Health Information Portability and Accountability Act (HIPAA) authorization before the initiation of any study-related procedures. * Subjects must be ≥18 years old; * The subject must have a diagnosis of adenocarcinoma of the colon and/or rectum with FDG PET/CT confirmed metastases to the liver; * The subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3; * The subject must be at least 4 weeks past any major intraabdominal surgery, including surgery to the liver; * Subjects with prior malignancies other than colon and/or rectum cancer are allowed, provided they have been treated with curative intent, and have no evidence of recurrence of that malignancy; * Each subject must have no more than 10 qualifying liver lesions that have been clinically confirmed metastatic adenocarcinoma of the colon by FDG PET/CT imaging. * If of childbearing potential, the subject has a negative urine pregnancy test within 48 hours before administration of Tc 99m Tilmanocept, has been surgically sterilized, or has been postmenopausal for at least 1 year Exclusion Criteria: * The subject is pregnant or lactating. * The subject has undergone any liver surgery, exclusive of a biopsy. * The subject has known sensitivity to dextran. * The subject has had preoperative chemotherapy, immunotherapy, or radiation therapy within the 10 days prior to Tc 99m Tilmanocept administration * Before the administration of Tc 99m Tilmanocept, has received any radiopharmaceutical within 7 radioactive half-lives of that radiopharmaceutical * Has received an investigational product within the 30 days prior to Tc 99m Tilmanocept administration